Emergent BioSolutions | EBS - Ativos





Ativos Alterar Data
Acadia Pharmaceuticals USD 1.56B 233.42M 2025-12
Akebia Therapeutics USD 376.56M 12.41M 2025-12
ALKERMES USD 2.49B 157.48M 2025-12
Alnylam Pharmaceuticals USD 4.97B 114.67M 2025-12
Amarin USD 659.81M 10.31M 2025-09
ANI Pharmaceuticals USD 1.44B 32.22M 2025-12
BioMarin Pharmaceutical USD 7.59B 20.85M 2025-12
Coherus Biosciences USD 516.52M 77.05M 2025-09
Emergent BioSolutions USD 1.82B 69.9M 2023-12
Exact Sciences USD 5.86B 39.38M 2025-12
Exelixis USD 2.84B 20.87M 2025-12
Glaxosmithkline GBP 82.45B 23.19B 2025-09
Heron Therapeutics USD 248.95M 16.86M 2025-09
Ionis Pharmaceuticals USD 3.52B 490.91M 2025-12
Ironwood Pharmaceuticals USD 396.06M 53.12M 2025-09
Lexicon Pharmaceuticals USD 225.58M 72.09M 2025-06
Lonza CHF 19.73B 1.85B 2024-12
Merck USD 129.55B 12.02B 2025-09
Moderna USD 12.34B 203M 2025-12
Myriad Genetics USD 728.1M 50.8M 2025-09
Nektar Therapeutics USD 301.35M 93.81M 2025-09
Neurocrine Biosciences USD 4.63B 365.8M 2025-12
Pacira USD 1.26B 32.66M 2025-12
Pfizer USD 208.73B 2.64B 2025-09
PTC Therapeutics USD 2.9B 255.07M 2025-12
Sanofi EUR 126.81B 2.99B 2025-12
Sarepta Therapeutics USD 3.35B 143.73M 2025-12
United Therapeutics USD 7.88B 528.9M 2025-12
Vanda Pharmaceuticals USD 488.95M 112.19M 2025-12
Xoma USD 263.15M 39.7M 2025-09